IN8bio, Inc. (INAB) Form 8-K Summary
Business Context and Reporting Period
IN8bio, Inc., a Delaware corporation, filed this Current Report on Form 8-K on December 18, 2025. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities. The company is an emerging growth company focused on developing product candidates, specifically referencing INB-619 in the context of future milestones.
Key Financial Metrics and Transaction Details
The filing details a two-closing private placement structure with the following financial parameters:
- Initial Closing: Anticipated on or about December 22, 2025.
- Initial Proceeds: Approximately $20.1 million in gross proceeds.
- Securities Issued (Initial): 5,127,029 shares of Common Stock and Pre-Funded Warrants to purchase up to 9,452,677 shares.
- Pricing: Common Stock at $1.38 per share; Pre-Funded Warrants at $1.3799 per warrant.
- Second Closing (Contingent): Up to an additional $20.1 million in gross proceeds for up to 14,579,706 shares or Pre-Funded Warrants.
- Total Potential Proceeds: Approximately $40.2 million (Initial + Second Closing).
The filing does not provide current revenue, profit, cash flow, or debt figures, as this is a transactional report rather than a periodic financial statement.
Material Changes and Conditions
The Second Closing is contingent upon the "Second Closing Trigger," which requires:
- Scientific Milestone: Presentation of animal model data for the INB-619 product candidate between the Initial Closing and December 31, 2026.
- Price Threshold: A volume-weighted average price (VWAP) of at least 200% of the Share Price ($2.76) over five consecutive trading days within 90 days of the milestone announcement, OR a waiver by majority investors.
The Company retains the right to reduce the Second Closing investment amount pro rata by cash proceeds received from licensing or collaboration agreements not involving equity issuance.
Outlook, Risks, and Agreements
Registration Rights: The Company agreed to file a registration statement within 30 days of each closing and use reasonable best efforts to have it declared effective within 90 days. Failure to meet these deadlines may result in liquidated damages of 1% of the investment amount per 30-day period.
Investor Rights: Investors have the right to participate in subsequent equity financings up to 200% of their initial investment amounts until December 31, 2026.
Risks: The transaction is subject to customary closing conditions. The Pre-Funded Warrants are subject to beneficial ownership limitations (generally capped at 19.99% unless adjusted by the holder).
Key Facts for Investor Verification
- Verify the closing date of the Initial Closing (expected December 22, 2025) and the actual net proceeds after placement agent fees.
- Monitor the progress of the INB-619 animal model data presentation to determine if the Second Closing Trigger is met.
- Track the stock price relative to the $2.76 threshold (200% of $1.38) following any INB-619 milestone announcement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific terms regarding the reduction of the Second Closing commitment based on non-equity collaboration proceeds.
- Confirm the filing and effectiveness of the Registration Statement for the resale of securities to ensure liquidity for investors.